BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance
BillionToOne reported Q1 2026 revenue of $108.4 million, up 84% year-over-year, driven by a 44% increase in test volume and a 28% increase in average selling price. The company raised full-year 2026 revenue guidance to $450 million to $465 million, representing 48% to 52% growth over 2025, up from prior guidance of $430 million to $445 million.
Key figures
- Eps
- 0.34
- Revenue
- 108400000
- Guidance
- 2026 revenue $450M-$465M, raised from $430M-$445M
- Revenue Yoy
- 84%
- Fcf
- 11000000
- Gross margin
- 73%
- Gross profit
- 79100000
- Oncology revenue
- 10700000
- Operating income
- 17800000
- Operating margin
- 16%
- Prenatal revenue
- 96500000
- Total tests delivered
- 188000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.